1 / 4

ANGINA PECTORIS TREATMENT MARKET ANALYSIS,2018-2026

ngina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heartu2019s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. <br>

akshay925
Download Presentation

ANGINA PECTORIS TREATMENT MARKET ANALYSIS,2018-2026

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Angina Pectoris Treatment Market, by Drug Class (Beta Angina Pectoris Treatment Market, by Drug Class (Beta Blockers, Calcium Channel Blockers, Nitrates, Blockers, Calcium Channel Blockers, Nitrates, Angiotensin-converting Enzyme Inhibitors, and Other) by Angiotensin-converting Enzyme Inhibitors, and Other) by Indication (Stable Angina and Unstable Angina) - Global Indication (Stable Angina and Unstable Angina) - Global Industry Insights, Trends, Outlook, and Opportunity Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 Analysis, 2018-2026 Angina pectoris is a medical term for chest pain or discomfort, which is caused due to coronary heart disease. Angina pectoris mainly occurs when heart muscle are unable to receive adequate blood. This condition usually occurs when one or more of the heart’s arteries are narrowed or blocked, which is also known as ischemia. Angina pectoris leads to uncomfortable pressure, fullness, squeezing or pain in the center of the chest. The factors that trigger stable angina pectoris include, emotional stress, exposure to very hot or cold temperature, heavy meals or smoking. Angina pectoris can be diagnosed by an electrocardiogram and angiography and could be treated by medication, change in life style, and surgery. A minimal invasive procedure known as angioplasty is also used to treat the angina pectoris. The pain or discomfort caused by angina pectoris is relieved with rest and nitroglycerin. Nitroglycerin relaxes the coronary arteries and other blood vessels by increasing the blood flow to the heart vessels. Angina Pectoris Treatment Market Taxonomy Angina Pectoris Treatment Market Taxonomy By Drug Class: By Drug Class: Beta blockers • Calcium channel blockers • Nitrates • Angiotensin-converting enzyme inhibitors • Other •

  2. By Indication: By Indication: Stable Angina • Unstable Angina • New product launches and strong pipeline is expected to fuel the growth of angina pectoris New product launches and strong pipeline is expected to fuel the growth of angina pectoris treatment market treatment market Espero announced in June 2016, that the company received approval from the U.S. Food and Drug Administration (FDA) for GoNitro (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris, due to coronary artery disease. In February 2016, AstraZeneca sold the rights of its two medicines Plendil and Imdur for US $500Mn. China Medical System Holdings (CMS) agreed to pay AstraZeneca US $310 million for commercialization rights of Plendil (felodipine) in China. Plendil is a calcium antagonist indicated for both hypertension and the prophylaxis of the chronic stable angina pectoris. Whereas, Imdur is an oral extended-release formulation of isosorbide mononitrate indicated for the prevention of angina pectoris, due to coronary artery disease. Get PDF Brochure Of This Research Report @ : Get PDF Brochure Of This Research Report @ : https://www.coherentmarketinsights.com/insight/request-pdf/1158 https://www.coherentmarketinsights.com/insight/request-pdf/1158 Furthermore, Amgen offers a product named Corlanor (Ivabradine) for the treatment of angina pectoris in its pipeline (phase 3), which was presented by the company in year 2015 at Annual Scientific Session. In November 2016, Allergan also presented new data on BYSTOLIC (nebivolol) for the treatment of hypertension to lower blood pressure at the Annual American Heart Association Meeting in New Orleans. Whereas, Perrigo announced FDA approval of its abbreviated new drug application (ANDA) for Nitroglycerin Lingual Spray in 2013, the generic version of Shionogi's Nitrolingual Pumpspray indicated for acute attacks and prophylaxis of angina pectoris.

  3. Strategic activities by market players to increase their market share Strategic activities by market players to increase their market share Angina pectoris treatment market is driven by factors, such as increasing number of collaborations, product launches, and mergers and acquisition. For instance, Recordati acquired AstraZeneca blood pressure brand Metoprolol, in 2017, which is a beta-blocker used mainly for the conditions, such as angina pectoris, hypertension, and heart disorders. Furthermore, Pharmaceutical manufacturer Lupin received approval from U.S. FDA in 2017 to launch the generic version of the U.S WorldMeds’ nadolol drug indicated for the patients with angina pectoris and for the treatment of hypertension. Moreover, patent expiry of Ranolazine drug from Gilead Sciences, Inc. in 2019 would mark the opportunity for generic drug manufacturers in the global angina pectoris treatment market. Research Methodology Research Methodology Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include: Primary Research (Trade Surveys and Experts Interviews) Primary Research (Trade Surveys and Experts Interviews) • Desk Research Desk Research • Proprietor Data Analytics Model Proprietor Data Analytics Model • In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.

  4. The key players operating in the global market of angina pectoris treatment market include global market of angina pectoris treatment market include Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann- Abbott Laboratories, Astra Zeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann- La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer La Roche Ltd., Allergan plc, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., and Sanofi SA. Inc., and Sanofi SA. ➔ Request Sample Copy of Research Report @ : Request Sample Copy of Research Report @ : https://www.coherentmarketinsights.com/insight/request-sample/1158 https://www.coherentmarketinsights.com/insight/request-sample/1158 About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com Email: sales@coherentmarketinsights.com

More Related